Aptorum Group Ltd., a clinical stage biopharmaceutical company, announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's Class A ordinary shares maintained a closing bid price of at least $1.00 for a minimum of 10 consecutive business days, meeting Nasdaq's criteria. This follows an initial notice from Nasdaq dated April 15, 2025, with a deadline of October 14, 2025. The company received formal notification from Nasdaq confirming the compliance, closing the matter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9505430-en) on August 04, 2025, and is solely responsible for the information contained therein.